

# VENOUS THROMBOEMBOLISM IN FOOT SURGERY: HOW BIG IS THE RISK, REALLY?

Mark Razzante, DPM, FACPM

Dean, College of Podiatric Medicine

Samuel Merritt University



**Samuel Merritt  
University**  
College of Podiatric Medicine



IN PARTNERSHIP WITH


**CMC**  
*Foundation*

COLLABORATIVE MEDICAL CONTENT  
AN EDUCATIONAL NONPROFIT

# What is the concern?

- NHS economic burden from **venous thromboembolic events (VTEs)** approx. £640m  
(Benjamin et al, 2021)
  - **Surgery, general anesthesia, post-operative immobilization, reduced weightbearing** can increase the risk of VTE
  - What is the real question:
    - How big is the risk?
    - Who is at risk?
-

# Symptomatic Rates




Jameson SS et al. *Venous thromboembolic events following foot and ankle surgery in the English NHS*. J Bone Joint Surg Br.  
Mizel MS et al. *Symptomatic venous thromboembolism after foot and ankle surgery*. Foot Ankle Int.

# Mechanical Prophylaxis for All

- Early mobilization
  - Hydration
  - Calf exercises
  - Compression when appropriate
-

# Worldwide Survey (JFAS 2024)

- 693 orthopedic foot and ankle surgeons
  - 97% stated prophylaxis is necessary in foot and ankle surgery
  - Acetylsalicylic acid (Aspirin), LMWH, Direct-oral anticoagulants used in order
  - Prior DVTs, immobility, obesity, inherited thrombophilia main risk factors for use
  - **Only 49% aware of risk assessment scores** (31% use them)
-



Outcome	Number of Surgeons Number/Total Number (%)
<i>Prophylaxis against VTE in elective and traumatic foot and/or ankle surgery is</i>	
Mandatory	161/691 (23)
Sometimes needed	508/691 (74)
Waste of time	22/691 (3)
<i>Why do you prescribe prophylaxis?</i>	
Prevents VTE which outweighs bleeding risk	342/680 (50)
Act in accordance with hospital/national guideline	157/680 (23)
Clinical experience shows a beneficial effect	70/680 (10)
Risk of complications is very small	111/680 (16)
<i>Main reason to prescribe prophylaxis</i>	
As answered before	289/494 (59)
Feel compelled by patients' request	8/494 (2)
For medico-legal reasons	170/494 (34)
Other, please specify	27/494 (5)

Abbreviations: FA; foot and/or ankle; VTE, venous thromboembolism.

# Guidelines & Position Statements

- National Institute for Health and Care Excellence NG89
  - American College of Foot and Ankle Surgeons
  - International Consensus Meeting
  - American Orthopedic Foot and Ankle Society
  - British Orthopedic Foot and Ankle Society
-

# NICE NG89

- No blanket recommendation for foot and ankle
  - Patients undergoing lower extremity orthopedic surgery (especially when reduced WB post-op) tailored to individual risk factors
-

## NICE

- Risk assess **every** patient
- Consider prophylaxis if:
  - Surgery >90 minutes
  - Patient **cannot weight-bear**
  - Patient has **significant VTE risk factors**
- Immobilization (cast/boot) = VTE risk  
→ prophylaxis based on **risk–benefit**
- **No routine anticoagulation for low-risk, mobile patients**
- Encourage **early mobilization**

## CAPRINI

- Point-based **VTE risk scoring tool**
- Assigns points for:
  - **Age, BMI, surgery duration**
  - **Immobilization (cast/boot)**
  - **Cancer, OCP/HRT, varicose veins**
  - **History of VTE or thrombophilia**
- Higher total score = higher VTE risk
- **Score  $\geq 5$** : consider chemical prophylaxis
- Not validated specifically for foot/ankle, but widely used

# ACFAS Clinical Consensus Statement 2017

- Routine chemical prophylaxis is not warranted
  - Foot and ankle surgery
  - Injuries requiring immobilization

Risk factors for venous thromboembolism disease during management of foot and ankle conditions		
Patient Specific	Treatment Specific	Surgery/Injury Specific
<b>Primary</b>		
Personal history of VTED	Immobilization >4 wk	
Hypercoagulability		
Active/recent (<6 mo) cancer		
<b>Secondary</b>		
Advanced age (>60)*	Non-weightbearing	Achilles tendon rupture <sup>†</sup>
Obesity (BMI >30)	Hospitalization	Ankle fracture <sup>†</sup>
Family history of VTED	Bed rest	Total ankle replacement
OCP or HRT use <sup>†</sup>		Hindfoot arthrodesis
Varicose veins		General anesthesia
Diabetes mellitus or >1 comorbidity		
Severe foot/ankle injury		

# AOFAS Position Statement 2020

- Exact risk is unclear
    - Wide variety of injuries, surgeries, rehab protocols
    - If sufficient risk factors are present, VTE prophylaxis should be considered
    - **“Sufficient risk” definition is unclear**
-

# AOFAS Position Statement 2020

- Key data points from the review:
    - RCT Plaster cast immobilizations
      - 4.3% VTE without prophylaxis vs. 0% VTE with prophylaxis
    - VTE rate 1% in over 45,000 patients undergoing ankle fracture ORIF
    - 2,600 patients undergoing elective foot and ankle surgery
      - VTE 0.42% with aspirin vs. 1.43% with no prophylaxis
    - In general, VTE rates around 1-2%
-

# ICM-VTE 2022

- Non-weightbearing increases the risk for VTE
    - Mitigate this risk by load-bearing at least 50% on the surgical limb
  - **Patient specific risk factors are likely to contribute more than surgical procedure (excluding ATR)**
    - Age >50 years
    - Splint or cast immobilization
    - Charlson Comorbidity index >2
    - Varicose Veins
    - History of DVT
    - Hypercoagulability disorder
    - Inflammatory arthritis
-

# ICM-VTE 2022

- Do not recommend routine prophylaxis in low-risk patients undergoing forefoot or midfoot surgeries, especially if immediate WB
  - **Achilles tendon repair routine prophylaxis not routinely recommended, factor in comorbidities**
    - Same for rearfoot & ankle surgeries
-

# BOFAS 2025 VTE Position Statement

“**Routine use** of chemical thromboprophylaxis is **not beneficial for low risk patients** with foot and ankle injuries or those undergoing foot and ankle surgery.”

- Malhotra et al 2024

Increased risk categories:

- History of VTE, increased BMI – Mangwani et al 2015

- Achilles ruptures – Mangwani et al 2023

---

# Richey, Weintraub & Schubert, 2019

- 22,486 cohort retrospective study - **VTE incidence 0.9%**
- Predictive risk factors: The risk of VTE increased significantly with 3 or more risk factors

**Obesity**

**History of VTE**

**Postoperative NWB >2 weeks**

**Hormonal replacement use/oral contraception**

Anatomic location of surgery

Procedure duration >60 min

General Anesthesia

History of trauma

“Among patients with **3 or more risk factors**, the use of chemoprophylaxis **may be warranted**”

---

# Gouzoulis et al, 2022

- Retrospective 298,886 patients with isolated foot or ankle fractures identified

*1,661 (0.56%) had VTE within 90 days following fracture*

*27.3% within first week*

*49.8% within first 3 weeks*

*Risk factors:*


*Prior VTE*

*Factor V Leiden*

*Active cancer*

*Metatarsal/ankle/calcaneal fracture*

*Surgical treatment*



# Claveau et al, 2023

- Retrospective cohort study of patients undergoing prophylactic treatment
  - 5/425 (1.2%) diagnosed with VTE
    - No different than without prophylactic treatment in other publications*
  - 1/425 (0.2%) with PE
-

# Marder et al, 2024

- 468,699 surgeries

- Acute VTEs:

  - Achilles tendon repair 0.72%*

  - Ankle fracture surgery 0.33%*

  - Knee arthroscopy 0.29%*

  - Ankle arthroscopy 0.24%*

---

# VTE Following Achilles Tendon Rupture

- UK-Foot and ankle Thrombo-embolism (UK-FATE) audit 2025
  - 11,363 patients in total audit
    - 1084 with ATR
    - 24% surgical, 76% non-surgical
  - VTE 3.69% compared to 0.57% of all other foot and ankle surgeries
  - **6.5x more likely to have symptomatic VTE compared to other foot and ankle surgery**
  - No difference in comorbidity or treatment/rehab regimen between cohorts
-

# Take Home Points

- Average VTE risk after foot surgery is about 1%
- Use individualized assessments rather than blanket use
- Be cautious with Achilles Tendon ruptures
- Mechanical prophylaxis for all, chemoprophylaxis for the truly high risk

*We need better research to narrow down the true at-risk patients*

- The question really becomes:

*Is the adverse risk from prophylactic treatment greater than 1-2%?*

---



# THANK YOU

Mark Razzante, DPM, FACPM

Dean, College of Podiatric Medicine

Samuel Merritt University